Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBM-1152A Safety and PK in Healthy Chinese Subjects
NCT07439419Phase 1Completed
- Sponsor
- Joincare Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DBM-1152A in chronic obstructive pulmonary disease (COPD) and asthma, sponsored by Joincare Pharmaceutical. Primary endpoint: Overall Safety and Tolerability Profile at Day 14. Started Aug 2024; status: completed.
02
Drugs
DBM-1152A
03
Conditions
chronic obstructive pulmonary disease (COPD)asthma
Beyond the preview
Go deeper on NCT07439419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439419.